ITGAX and neoplasm: At 10 days post-tumor implantation, we did not observe any significant difference in the total frequency of CD45medCD11b+ microglia, NKp46+NK1.1+CD3− NK cells, CD11b+F4/80+Ly6C− MHCII+CD206− M1 macrophage, CD11b+F4/80+Ly6C− MHCII− CD206+ M2 macrophage, CD11b+F4/80− Ly6C+ monocytes, CD11c+MHCII+ DCs and DC subsets (CD103+ or CD11b+) as well as CD11b+Ly6G+ neutrophils in the tumor or spleen when comparing mice that received M002-treated CD4+ T cells to mice that received saline-treated cells (Fig. 3g and Supplementary Fig. 6b–f).